anifrolumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies (human origin); immunomodulator 5474 1326232-46-5

Description:

MoleculeDescription

Molfile

Synonyms:

  • anifrolumab
  • anifrolumab-fnia
  • saphnelo
  • MEDI-546
  • anifrolumab (genetical recombination)
Anifrolumab-fnia is a human IgG1kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR) with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs. Anifrolumab-fnia also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression as well as downstream inflammatory and immunological processes. Inhibition of type I IFN blocks plasma cell differentiation and normalizes peripheral T-cell subsets. Type I IFNs play a role in the pathogenesis of SLE. Approximately 60-80% of adult patients with active SLE express elevated levels of type I IFN inducible genes.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 14, 2022 EMA ASTRA ZENECA AB
July 30, 2021 FDA ASTRAZENECA AB
Sept. 27, 2021 PMDA ASTRAZENECA K.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA51 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA EPC N0000193967 Type I Interferon Receptor Antagonist
FDA MoA N0000193968 Type I Interferon Receptor Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Moderate to severe systemic lupus erythematosus (SLE) indication 55464009 DOID:9074




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interferon alpha/beta receptor 1 Membrane receptor ANTIBODY BINDING Kd 9.54 DRUG LABEL DRUG LABEL

External reference:

IDSource
38RL9AE51Q UNII
C4519739 UMLSCUI
CHEMBL2364653 ChEMBL_ID
DB11976 DRUGBANK_ID
D11082 KEGG_DRUG
9800 INN_ID
8258 IUPHAR_LIGAND_ID
018820 NDDF
4040742 VANDF
4040743 VANDF
2565265 RXNORM
349045 MMSL
39758 MMSL
d09779 MMSL
C582345 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SAPHNELO HUMAN PRESCRIPTION DRUG LABEL 1 0310-3040 INJECTION, SOLUTION 300 mg INTRAVENOUS BLA 26 sections
SAPHNELO HUMAN PRESCRIPTION DRUG LABEL 1 0310-3040 INJECTION, SOLUTION 300 mg INTRAVENOUS BLA 26 sections